Benign outcome of RSV infection in children with cancer

Peter D. Cole, Jin S. Suh, Kenan Onel, Jeffrey Stiles, Donald Armstrong, Ira J. Dunkel

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. High case-fatality rates have been reported among adults who develop respiratory syncytical virus (RSV) infection while being treated for oncologic diseases, particularly after bone marrow transplantation. Previous reports of RSV infection among children with primary and acquired immunodeficiencies describe increased morbidity compared with that seen in immunocompetent children, but there have been few reports describing the outcome of RSV infection specifically among pediatric oncology patients. Methods. We retrospectively reviewed the charts of all children being treated by the Pediatric Oncology Service at Memorial Sloan-Kettering Cancer Center who had positive tests for RSV between the Fall of 1994 and the Spring of 1998. Patients on the BMT Service were excluded from this analysis. Results. Eighteen RSV infections were identified among pediatric oncology patients, who were being treated with aggressive, predominantly alkylator-based chemotherapy for a variety of oncologic diagnoses. Nine episodes of RSV infection (50%) were treated with specific antiviral therapy. Only one death less than 100 days from the diagnosis of RSV infection occurred among these 18 patients and was attributed to progressive leukemia. The remaining patients recovered fully, although three were readmitted with respiratory symptoms within two weeks of discharge. Seven patients had concurrent infection with other pathogenic organisms. Conclusions. In striking contrast with the outcome of RSV infection in adult oncology patients, there may be low mortality associated with RSV infection in pediatric oncology patients. It is possible that scheduled antineoplastic therapy need not be delayed for these patients when the diagnosis of RSV infection is made.

Original languageEnglish (US)
Pages (from-to)24-29
Number of pages6
JournalMedical and Pediatric Oncology
Volume37
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Virus Diseases
Neoplasms
Pediatrics
Mortality
Alkylating Agents
Bone Marrow Transplantation
Antineoplastic Agents
Antiviral Agents
Leukemia
Viruses
Morbidity
Drug Therapy
Therapeutics
Infection

Keywords

  • Acquired immunodeficiency
  • Antineoplastic agents
  • Childhood
  • Infection
  • Respiratory syncytial virus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Cole, P. D., Suh, J. S., Onel, K., Stiles, J., Armstrong, D., & Dunkel, I. J. (2001). Benign outcome of RSV infection in children with cancer. Medical and Pediatric Oncology, 37(1), 24-29. https://doi.org/10.1002/mpo.1158

Benign outcome of RSV infection in children with cancer. / Cole, Peter D.; Suh, Jin S.; Onel, Kenan; Stiles, Jeffrey; Armstrong, Donald; Dunkel, Ira J.

In: Medical and Pediatric Oncology, Vol. 37, No. 1, 2001, p. 24-29.

Research output: Contribution to journalArticle

Cole, PD, Suh, JS, Onel, K, Stiles, J, Armstrong, D & Dunkel, IJ 2001, 'Benign outcome of RSV infection in children with cancer', Medical and Pediatric Oncology, vol. 37, no. 1, pp. 24-29. https://doi.org/10.1002/mpo.1158
Cole PD, Suh JS, Onel K, Stiles J, Armstrong D, Dunkel IJ. Benign outcome of RSV infection in children with cancer. Medical and Pediatric Oncology. 2001;37(1):24-29. https://doi.org/10.1002/mpo.1158
Cole, Peter D. ; Suh, Jin S. ; Onel, Kenan ; Stiles, Jeffrey ; Armstrong, Donald ; Dunkel, Ira J. / Benign outcome of RSV infection in children with cancer. In: Medical and Pediatric Oncology. 2001 ; Vol. 37, No. 1. pp. 24-29.
@article{98fa7bf23cfc459bbb5882cc51843315,
title = "Benign outcome of RSV infection in children with cancer",
abstract = "Background. High case-fatality rates have been reported among adults who develop respiratory syncytical virus (RSV) infection while being treated for oncologic diseases, particularly after bone marrow transplantation. Previous reports of RSV infection among children with primary and acquired immunodeficiencies describe increased morbidity compared with that seen in immunocompetent children, but there have been few reports describing the outcome of RSV infection specifically among pediatric oncology patients. Methods. We retrospectively reviewed the charts of all children being treated by the Pediatric Oncology Service at Memorial Sloan-Kettering Cancer Center who had positive tests for RSV between the Fall of 1994 and the Spring of 1998. Patients on the BMT Service were excluded from this analysis. Results. Eighteen RSV infections were identified among pediatric oncology patients, who were being treated with aggressive, predominantly alkylator-based chemotherapy for a variety of oncologic diagnoses. Nine episodes of RSV infection (50{\%}) were treated with specific antiviral therapy. Only one death less than 100 days from the diagnosis of RSV infection occurred among these 18 patients and was attributed to progressive leukemia. The remaining patients recovered fully, although three were readmitted with respiratory symptoms within two weeks of discharge. Seven patients had concurrent infection with other pathogenic organisms. Conclusions. In striking contrast with the outcome of RSV infection in adult oncology patients, there may be low mortality associated with RSV infection in pediatric oncology patients. It is possible that scheduled antineoplastic therapy need not be delayed for these patients when the diagnosis of RSV infection is made.",
keywords = "Acquired immunodeficiency, Antineoplastic agents, Childhood, Infection, Respiratory syncytial virus",
author = "Cole, {Peter D.} and Suh, {Jin S.} and Kenan Onel and Jeffrey Stiles and Donald Armstrong and Dunkel, {Ira J.}",
year = "2001",
doi = "10.1002/mpo.1158",
language = "English (US)",
volume = "37",
pages = "24--29",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Benign outcome of RSV infection in children with cancer

AU - Cole, Peter D.

AU - Suh, Jin S.

AU - Onel, Kenan

AU - Stiles, Jeffrey

AU - Armstrong, Donald

AU - Dunkel, Ira J.

PY - 2001

Y1 - 2001

N2 - Background. High case-fatality rates have been reported among adults who develop respiratory syncytical virus (RSV) infection while being treated for oncologic diseases, particularly after bone marrow transplantation. Previous reports of RSV infection among children with primary and acquired immunodeficiencies describe increased morbidity compared with that seen in immunocompetent children, but there have been few reports describing the outcome of RSV infection specifically among pediatric oncology patients. Methods. We retrospectively reviewed the charts of all children being treated by the Pediatric Oncology Service at Memorial Sloan-Kettering Cancer Center who had positive tests for RSV between the Fall of 1994 and the Spring of 1998. Patients on the BMT Service were excluded from this analysis. Results. Eighteen RSV infections were identified among pediatric oncology patients, who were being treated with aggressive, predominantly alkylator-based chemotherapy for a variety of oncologic diagnoses. Nine episodes of RSV infection (50%) were treated with specific antiviral therapy. Only one death less than 100 days from the diagnosis of RSV infection occurred among these 18 patients and was attributed to progressive leukemia. The remaining patients recovered fully, although three were readmitted with respiratory symptoms within two weeks of discharge. Seven patients had concurrent infection with other pathogenic organisms. Conclusions. In striking contrast with the outcome of RSV infection in adult oncology patients, there may be low mortality associated with RSV infection in pediatric oncology patients. It is possible that scheduled antineoplastic therapy need not be delayed for these patients when the diagnosis of RSV infection is made.

AB - Background. High case-fatality rates have been reported among adults who develop respiratory syncytical virus (RSV) infection while being treated for oncologic diseases, particularly after bone marrow transplantation. Previous reports of RSV infection among children with primary and acquired immunodeficiencies describe increased morbidity compared with that seen in immunocompetent children, but there have been few reports describing the outcome of RSV infection specifically among pediatric oncology patients. Methods. We retrospectively reviewed the charts of all children being treated by the Pediatric Oncology Service at Memorial Sloan-Kettering Cancer Center who had positive tests for RSV between the Fall of 1994 and the Spring of 1998. Patients on the BMT Service were excluded from this analysis. Results. Eighteen RSV infections were identified among pediatric oncology patients, who were being treated with aggressive, predominantly alkylator-based chemotherapy for a variety of oncologic diagnoses. Nine episodes of RSV infection (50%) were treated with specific antiviral therapy. Only one death less than 100 days from the diagnosis of RSV infection occurred among these 18 patients and was attributed to progressive leukemia. The remaining patients recovered fully, although three were readmitted with respiratory symptoms within two weeks of discharge. Seven patients had concurrent infection with other pathogenic organisms. Conclusions. In striking contrast with the outcome of RSV infection in adult oncology patients, there may be low mortality associated with RSV infection in pediatric oncology patients. It is possible that scheduled antineoplastic therapy need not be delayed for these patients when the diagnosis of RSV infection is made.

KW - Acquired immunodeficiency

KW - Antineoplastic agents

KW - Childhood

KW - Infection

KW - Respiratory syncytial virus

UR - http://www.scopus.com/inward/record.url?scp=0034953310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034953310&partnerID=8YFLogxK

U2 - 10.1002/mpo.1158

DO - 10.1002/mpo.1158

M3 - Article

C2 - 11466719

AN - SCOPUS:0034953310

VL - 37

SP - 24

EP - 29

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -